I agree. Here's the catch 22 - had we partnered with a big pharma, we would get the publicity but likely get screwed on the deal. This way, we don't get the publicity (until it really matters) and we negotiate favourable financial and commercial terms.
I think the only way we'll now get the publicity we need is if we move into another indication. Tom said today that they have enough money to conduct a P3 trial (x1) and enough financial flexibility to look at another indications. That was a key point for me. It seems they are also aware of the need to branch out. This partnership can facilitate that. Peptron has developed a sustained-release version of Exenatide ((SR)-Exenatide) to investigate its neuroprotective effects in Parkinson's disease (https://clinicaltrials.gov/ct2/show/NCT04269642).
- Forums
- ASX - By Stock
- Ann: Notice of Investor Call and Presentation
IXC
invex therapeutics ltd
Add to My Watchlist
0.00%
!
6.8¢

I agree. Here's the catch 22 - had we partnered with a big...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
6.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.110M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7402 | 6.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.8¢ | 31157 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7402 | 0.068 |
1 | 7500 | 0.067 |
1 | 7590 | 0.066 |
1 | 19607 | 0.051 |
1 | 25000 | 0.040 |
Price($) | Vol. | No. |
---|---|---|
0.078 | 31157 | 1 |
0.079 | 22388 | 1 |
0.080 | 10000 | 1 |
0.150 | 713 | 1 |
0.000 | 0 | 0 |
Last trade - 10.04am 02/04/2025 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |
Day chart unavailable
The Watchlist
AVM
ADVANCE METALS LIMITED
Adam McKinnon, MD
Adam McKinnon
MD
SPONSORED BY The Market Online